LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.
The drug development company said at its annual general meeting the phase two trials in metastatic breast cancer and subarachnoid haemorrhage, a type of stroke, will make an important value inflexion points in the clinical development of its lead product candidate SFX-01.
The company had previously announced positive results from its metastatic breast cancer study and said patient recruitment in the subarachnoid haemorrhage study continued on track.
Evgen shares were trading down 5.7% at 16.50 pence.
